Your browser doesn't support javascript.
National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments.
Gelfand, Joel M; Armstrong, April W; Bell, Stacie; Anesi, George L; Blauvelt, Andrew; Calabrese, Cassandra; Dommasch, Erica D; Feldman, Steven R; Gladman, Dafna; Kircik, Leon; Lebwohl, Mark; Lo Re, Vincent; Martin, George; Merola, Joseph F; Scher, Jose U; Schwartzman, Sergio; Treat, James R; Van Voorhees, Abby S; Ellebrecht, Christoph T; Fenner, Justine; Ocon, Anthony; Syed, Maha N; Weinstein, Erica J; Gondo, George; Heydon, Sue; Koons, Samantha; Ritchlin, Christopher T.
  • Gelfand JM; Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania; Department of Biostatistics, Epidemiology and Informatics and Center for Clinical Epidemiology and Biostatistics Perelman School of Medicine, University of Pennsylvania, Philadelphia, Penns
  • Armstrong AW; Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles, California.
  • Bell S; National Psoriasis Foundation, Portland, Oregon.
  • Anesi GL; Department of Biostatistics, Epidemiology and Informatics and Center for Clinical Epidemiology and Biostatistics Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Division of Pulmonary, Allergy, and Critical Care, University of Pennsylvania Perelman School of Medic
  • Blauvelt A; Oregon Medical Research Center, Portland, Oregon.
  • Calabrese C; Department of Rheumatology and Immunology, Cleveland Clinic, Cleveland, Ohio.
  • Dommasch ED; Department of Dermatology, Harvard Medical School, Boston, Massachusetts.
  • Feldman SR; Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, North Carolina.
  • Gladman D; Krembil Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada; University of Toronto, Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada.
  • Kircik L; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York; Indiana University Medical Center, Indianapolis, Indiana.
  • Lebwohl M; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Lo Re V; Department of Biostatistics, Epidemiology and Informatics and Center for Clinical Epidemiology and Biostatistics Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Division of Infectious Diseases, University of Pennsylvania Perelman School of Medicine, Philadelphia,
  • Martin G; Dermatology Associates, Maui, Hawaii.
  • Merola JF; Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Scher JU; Department of Medicine, Division of Rheumatology, New York University Grossman School of Medicine and New York University Langone Orthopedic Hospital, New York, New York.
  • Schwartzman S; Department of Rheumatology, Hospital for Special Surgery, New York, New York.
  • Treat JR; Department of Pediatric Dermatology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
  • Van Voorhees AS; Department of Dermatology, Eastern Virginia Medical School, Norfolk, Virginia.
  • Ellebrecht CT; Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.
  • Fenner J; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Ocon A; Division of Allergy, Immunology, and Rheumatology Division, University of Rochester Medical Center, Rochester, New York.
  • Syed MN; Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.
  • Weinstein EJ; Division of Infectious Diseases, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.
  • Gondo G; National Psoriasis Foundation, Portland, Oregon.
  • Heydon S; National Psoriasis Foundation, Portland, Oregon.
  • Koons S; National Psoriasis Foundation, Portland, Oregon.
  • Ritchlin CT; Division of Allergy, Immunology, and Rheumatology Division, University of Rochester Medical Center, Rochester, New York.
J Am Acad Dermatol ; 84(5): 1254-1268, 2021 05.
Article in English | MEDLINE | ID: covidwho-1014571
ABSTRACT

OBJECTIVE:

To update guidance regarding the management of psoriatic disease during the COVID-19 pandemic. STUDY

DESIGN:

The task force (TF) includes 18 physician voting members with expertise in dermatology, rheumatology, epidemiology, infectious diseases, and critical care. The TF was supplemented by nonvoting members, which included fellows and National Psoriasis Foundation staff. Clinical questions relevant to the psoriatic disease community were informed by inquiries received by the National Psoriasis Foundation. A Delphi process was conducted.

RESULTS:

The TF updated evidence for the original 22 statements and added 5 new recommendations. The average of the votes was within the category of agreement for all statements, 13 with high consensus and 14 with moderate consensus.

LIMITATIONS:

The evidence behind many guidance statements is variable in quality and/or quantity.

CONCLUSIONS:

These statements provide guidance for the treatment of patients with psoriatic disease on topics including how the disease and its treatments affect COVID-19 risk, how medical care can be optimized during the pandemic, what patients should do to lower their risk of getting infected with severe acute respiratory syndrome coronavirus 2 (including novel vaccination), and what they should do if they develop COVID-19. The guidance is a living document that is continuously updated by the TF as data emerge.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Psoriasis / COVID-19 Vaccines / COVID-19 Type of study: Observational study / Prognostic study Topics: Long Covid / Vaccines Limits: Humans Country/Region as subject: North America Language: English Journal: J Am Acad Dermatol Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Psoriasis / COVID-19 Vaccines / COVID-19 Type of study: Observational study / Prognostic study Topics: Long Covid / Vaccines Limits: Humans Country/Region as subject: North America Language: English Journal: J Am Acad Dermatol Year: 2021 Document Type: Article